International Psoriasis Council

ADVANCING PSORIASIS RESEARCH AND TREATMENT THROUGH EDUCATION, COLLABORATION, AND INNOVATION

EDUCATION - TO ENHANCE THE CARE OF PATIENTS WORLDWIDE, IPC DELIVERS A VARIETY OF EDUCATIONAL PROGRAMS FOR HEALTH CARE PROFESSIONALS AROUND THE WORLD. IN RESPONSE TO THE CANCELLATION OF MANY IN-PERSON CONGRESSES, IPC PARTICIPATED IN THESE CONFERENCES VIRTUALLY. IN ADDITION, A GLOBAL WEBINAR SERIES WAS DELIVERED, AND IPC FELLOWS PARTICIPATED IN ONLINE ACTIVITIES. IPC EXPERTS SPOKE ABOUT VARIOUS TOPICS, INCLUDING COVID-19 AND PSORIASIS; IPC'S DISEASE SEVERITY RECLASSIFICATION PROJECT AND ITS IMPLICATION IN CLINICS; THE FUTURE OF TELEDERMATOLOGY; DISEASE MODELS FOR BIOMARKER RESEARCH; PSORIASIS AND PSORIATIC ARTHRITIS BIOMARKERS; AND MACHINE LEARNING APPROACHES FOR PSORIASIS RESEARCH; AMONG OTHERS. IPC ALSO PRODUCED ON-LINE CONTENT IN THE FORM OF VIDEOS, EXPERT COMMENTARIES AND...(CONTINUED ON SCH O)(EDUCATION CONTINUED) CONGRESS REPORTS. THROUGH THESE ACTIVITIES, MORE THAN 30,000 PROFESSIONALS WERE PROVIDED WITH DISEASE INFORMATION, MEDICAL EDUCATION, AND CLINICAL RESOURCES.

RESEARCH - COVID-19: THE IPC BOARD OF DIRECTORS HAS CONTINUED TO MONITOR THE PANDEMIC'S EFFECT ON PSORIASIS CARE. THE WEB-BASED COVID-19 RESOURCE CENTER HAS RECEIVED OVER 3,200 VISITS. THE RESOURCE CENTER INCLUDES VIDEOS FEATURING REAL-WORLD EXPERIENCES FROM PHYSICIANS AT THE FOREFRONT OF THE PANDEMIC, EXPERT OPINIONS ON PUBLISHED MANUSCRIPTS, LINKS TO TREATMENT GUIDELINES, AND INFORMATION ON THE PSOPROTECT AND PSOPROTECTME COVID-19 REGISTRIES. IPC IS A GLOBAL PARTNER OF THE PSOPROTECT AND PSOPROTECTME COVID-19 REGISTRIES. WE HAVE ENCOURAGED THE IPC COMMUNITY TO REPORT OUTCOMES OF COVID-19 IN INDIVIDUALS WITH PSORIASIS. THE REGISTRY NOW INCLUDES 1,272 PARTICIPANTS. ADDITIONALLY, SIX COMMENTARIES ON KEY MANUSCRIPTS HAVE BEEN POSTED TO OUR WEBSITE AND HAVE RECEIVED A COMBINED TOTAL OF 2,200 VIEWS...(CONTINUED ON SCH O)(RESEARCH CONTINUED) IPC ISSUED A SURVEY TO THE COUNCILORS TO RECEIVE RECOMMENDATIONS FOR ACTIVITIES IN THE FUTURE YEARS. PUSTULAR PSORIASIS: IPC'S PUSTULAR PSORIASIS PROJECT AIMS TO IMPROVE THE UNDERSTANDING OF THIS RARE AND LIFE-THREATENING DISEASE AND WILL INCLUDE ACTIVITIES TO IMPROVE PATIENT CARE. THE RECENTLY FORMED WORKING GROUP IS CURRENTLY DEVELOPING PRELIMINARY PLANS FOR 2022, WHICH MAY INCLUDE: DEFINING THE OBJECTIVES AND ADDRESSING THE FEASIBILITY OF REAL-WORLD DATA COLLECTION THROUGH INTERNATIONAL COLLABORATION WITH PUSTULAR PSORIASIS CLINICAL CENTERS AND LABORATORIES; REACHING A GLOBAL CONSENSUS ON PUSTULAR PSORIASIS SCORING ASSESSMENTS; INITIATING INTRA-RATER AND INTER-RATER VARIABILITY VALIDATION STUDIES; DEVELOPING TRAINING MODULES ON PUSTULAR SCORES AND CERTIFICATION FOR CLINICAL TRIAL INVESTIGATORS; AND HOSTING AN EXPERT ROUNDTABLE/MEETING ON PUSTULAR PSORIASIS IN ASIA.

ACCESS TO CARE - RECLASSIFICATION OF DISEASE SEVERITY: IN 2019, IPC PUBLISHED A CONSENSUS STATEMENT THAT REJECTED THE TRADITIONAL CLASSIFICATIONS OF PSORIASIS AS MILD, MODERATE, AND SEVERE AND INSTEAD RECOMMENDED THAT PSORIASIS PATIENTS BE CLASSIFIED AS EITHER A CANDIDATE FOR TOPICAL THERAPY OR A CANDIDATE FOR SYSTEMIC THERAPY. OVER THE PAST YEAR, IPC HAS EDUCATED OVER 5,000 DERMATOLOGISTS, THROUGH MASTERCLASSES, CONGRESS SYMPOSIA, AND OUR TAKE TEN VIDEO PROJECT, ON THE VALUE OF USING THE NEW CATEGORIZATION IN THEIR DAILY PRACTICE TO INCREASE THE NUMBER OF PATIENTS RECEIVING THE APPROPRIATE TREATMENT. IN ADDITION, IPC WORKED WITH NATIONAL ENTITIES TO SECURE INCLUSION OF THE CLASSIFICATION IN THE UPDATE OF TWO EUROPEAN TREATMENT GUIDELINES AND PARTNERED WITH THE NPF TO ANALYZE THEIR ANNUAL...(CONTINUED ON SCH O)(ACCESS TO CARE CONTINUED) PATIENT SURVEY DATE. THE ANALYSIS IS COMPLETE, AND A MANUSCRIPT IS CURRENTLY IN DEVELOPMENT. TELEMEDICINE: IPC CONVENED A WORKING GROUP TO ESTABLISH A ROAD MAP FOR HOW IPC CAN AID THE DEVELOPMENT AND IMPLEMENTATION OF TELEMEDICINE FOCUSED ON PSORIASIS DIAGNOSIS AND MANAGEMENT. THE TELEMEDICINE WORKING GROUP, CHAIRED BY ALEXANDER NAVARRINI AND CO-CHAIRED BY JOEL GELFAND, IS DEVELOPING CONSENSUS STATEMENTS REGARDING TELEMEDICINE IN PSORIASIS MANAGEMENT. FOLLOWING THE PUBLISHING OF THE STATEMENTS, THE WORKING GROUP WILL CONTINUE TO WORK TOWARD OTHER ACTIONS. A CONSENSUS MANUSCRIPT, INCLUDING 34 STATEMENTS IS IN DEVELOPMENT AND WILL BE PUBLISHED NEXT YEAR.GLOBAL PSORIASIS ATLAS: PHASE TWO OF THE GLOBAL PSORIASIS ATLAS (GPA) PROJECT HAS BEEN INITIATED IN PARTNERSHIP WITH THE ILDS (INTERNATIONAL LEAGUE OF DERMATOLOGICAL SOCIETIES) AND IFPA (INTERNATIONAL FEDERATION OF PSORIASIS ASSOCIATIONS). THE UNIVERSITY OF MANCHESTER WILL CONTINUE TO SERVE AS THE LEAD ACADEMIC INSTITUTION FOR THE PROJECT. WORKSTREAMS FOR PHASE TWO INCLUDE: - EPIDEMIOLOGY OF PSORIASIS, - EARLY DIAGNOSIS OF PSORIASIS, - COMORBID DISEASE BURDEN OF PSORIASIS, AND - THE ECONOMIC IMPACT OF PSORIASIS.OVER THE PAST YEAR, FIVE MANUSCRIPTS WERE PUBLISHED ON TOPICS INCLUDING CANCER, PSORIASIS PREVALENCE IN THE UNITED STATES, THE INCIDENCE OF PSORIASIS IN CHILE, AND THE DEVELOPMENT OF CLINICAL DIAGNOSTIC CRITERIA FOR PLAQUE PSORIASIS. STUDIES COMPLETED IN TAIWAN AND MALAYSIA HAVE PUBLICATIONS PENDING SUBMISSION OR ACCEPTANCE. NEW STUDIES ARE ALSO UNDERWAY IN GREENLAND, NEW FOUNDLAND, AND QATAR.

OUTREACH AND OTHER PROGRAMS - IPC PARTICIPATED VIRTUALLY IN SEVERAL CONGRESSES TO GROW ITS REACH AND INFLUENCE THROUGHOUT THE WORLD. CONGRESSES INCLUDED THE SOCIETY OF INVESTIGATIVE DERMATOLOGY, THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, THE 6TH WORLD PSORIASIS & PSORIATIC ARTHRITIS CONFERENCE, THE EUROPEAN SOCIETY OF DERMATOLOGICAL RESEARCH, AND THE REUNION ANUAL DE DERMATOLOGOS LATINOAMERICANOS. EACH CONGRESS IS CHARGED WITH EDUCATING DERMATOLOGISTS AND SHARING BEST PRACTICES FOR IMPROVED CLINICAL CARE.